The Influence of Epigenetic Modification in OPRM1 on Postoperative Analgesia and Side Effect Induced by μ-opioid Receptor Agonists
| Registry | NCT03135795 |
|---|---|
| Status | Unknown |
| Phase | Phase 4 |
| Study type | Interventional; na, single group, masking: none, screening |
| Enrollment | 100 (Estimated) |
| Sponsor | Huazhong University of Science and Technology (Other) |
| Conditions | Epigenetics |
| Interventions | Sufentanil, dexmedetomidine, propofol, Rocuronium, sevoflurane, remifentanil, Parecoxib (Drug) |
| Dates | start 2017-02-06, primary completion 2017-05-31 (estimated), completion 2017-05-31 (estimated), first posted 2017-05-01, last updated 2017-05-01 |
| Locations | 1 site in China |
Related Papers Related Patents Related Grants Related Experts
All trials for Epigenetics All trials of Sufentanil All trials of dexmedetomidine
To explore the epigenetic mechanism of postoperative analgesia and side effect induced by μ-opioid Receptor Agonists presented with sufentanil among general population.
Patients were interviewed the day before surgery, and taught about the use of PCA pump and VAS. Pressure pain threshold(PPT) and pressure pain tolerance(PTO) were collected before surgery.
Dexmedetomidine1μg/Kg,sufentanil 0.5μg/Kg, propofol 2mg/Kg and rocuronium 0.6mg/Kg were given intravenously for induction. Anesthesia was maintained with inhalation of 1% sevoflurane and infusion of remifentanil (0.2-0.4ug/kg/min) and propofol (6-10mg/kg/h). Aterial blood pressure(ABP),central venous pressure(CVP),SPO2, HR,ETCO2,T and Narcotrend were monitored. Before incision, parecoxib 40mg was given intravenously, and PCA with sufentanil 1ug/ml was started immediately after surgery, suing a controlled infusion pump. The pump was programmed to use a loading dose of 2ml, background infusion at 2m/h, PCA dose of 1ml, lockout time of 10min, and maximal dose of 12ml with 1 h period.
VAS(static), VAS(dynamic), Ramssay, HR, NBP, SpO2, PCA pressing frequency, PCA comsumption were recorded 6h, 12h, 24h, 48h after surgery. Side effects such as nausea, vomiting, respiratory depression; pruritus; abdominal distention; urinary retention and dizziness were also recorded, and corresponding treatment were given.
EDTA anti-coagulated blood was collected from a central venous catheter during the operation. Genomic DNA was extracted from the blood samples, and characteristics and degree of DNA methylation of the gene OPRM1 were analysed.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| patients undergoing pancreatectomy | Experimental | Drug: Sufentanil; Drug: dexmedetomidine; Drug: propofol; Drug: Rocuronium; Drug: sevoflurane; Drug: remifentanil; Drug: Parecoxib | patients undergoing pancreatectomy received dexmedetomidine 1μg/Kg,sufentanil 0.5μg/Kg, propofol 2mg/Kg,rocuronium 0.6mg/Kg for induction.And received sevoflurane(1-2%), remifentanil(0.1-0.2ug/kg/min) and propofol(0.3-0.6mg/kg/h) for maintenance. Parecoxib 40mg was given single intravenously before incision. And PCA with sufentanil 1ug/ml was started immediately after surgery. |
Sex: All, ages: 35 Years to 60 Years
Inclusion Criteria: * American Society of Anesthesiologists physical status Ⅰ-Ⅱ ; * Weight 50-75 kg; Exclusion Criteria: * Long history of alcohol or analgesic drugs(including opioid ) abuse; * Heavy smoking; * Motion sickness; * Long history of PONV; * Chronic pain; * Complicated with severe heart、brain or kidney disease.
| Facility | City | Country | Status |
|---|---|---|---|
| Department of Anaesthesiology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology | Wuhan, Hubei | China | Recruiting |